Efficacy and safety of avalglucosidase alfa in Japanese patients with late-onset and infantile-onset Pompe diseases: A case series from clinical trials
Background: The efficacy and safety of avalglucosidase alfa for Pompe disease (PD) have been demonstrated in a global Phase 3 trial (COMET) in patients with late-onset PD (LOPD) and a global Phase 2 trial (Mini-COMET) in patients with infantile-onset PD (IOPD). This case series examines the individu...
Saved in:
| Main Authors: | Madoka Mori-Yoshimura, Hirotaka Ohki, Hideaki Mashimo, Kenji Inoue, Satoko Kumada, Takashi Kiyono, Akihiro Arimori, Mitsunobu Ikeda, Hirofumi Komaki |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Molecular Genetics and Metabolism Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214426924001162 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful desensitization protocol to alglucosidase and avalglucosidase alfa in a patient with infantile-onset Pompe disease
by: Miriam Gendive, et al.
Published: (2025-06-01) -
Five-Year Outcomes of Patients with Pompe Disease Identified by the Pennsylvania Newborn Screen
by: Hayley A. Ron, et al.
Published: (2025-02-01) -
Clinical examination of patients with late-onset Pompe disease: typical and not typical symptoms and signs
by: S. S. Nikitin
Published: (2020-01-01) -
Cipaglucosidase alfa and miglustat for treatment of late-onset Pompe disease (LOPD): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
by: Elizabeth K. Baker, et al.
Published: (2025-01-01) -
Late-onset Pompe disease with phenotype of the limb-girdle muscular dystrophy
by: S. A. Kurbatov, et al.
Published: (2015-09-01)